Pierandrea Muglia

Pierandrea Muglia, MD, currently serves as the Chief Medical Officer and a Board Member at Saniona since May 2023. Additionally, Pierandrea is the Founder and President of GRIN Therapeutics, a clinical-stage biotechnology company focused on developing treatments for children with genetically defined developmental epileptic encephalopathies. As Managing Director of Ichnos srl since May 2020, Pierandrea provides consultancy services for Biotech, Startups, and Pharma companies working on novel therapeutics for CNS disorders. Previous experience includes leadership roles such as Chief Medical Officer and Head of Clinical Development at Handl Therapeutics, and Vice President at UCB, overseeing Neurology strategy and early clinical pipeline development. Pierandrea co-founded and served as CMO at Aniona and contributed to exploratory medicine at NeuroSearch. Educational credentials include a Postdoctorate in Psychiatric Genetics from the University of Toronto and clinical training in Child and Adolescent Neuropsychiatry at Università degli Studi di Cagliari.